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ABSTRACT
Introduction: Tacrolimus (Tac) is the cornerstone of immunosuppressive therapy after solid organ trans-
plantation and will probably remain so. Excluding belatacept, no new immunosuppressive drugs were
registered for the prevention of acute rejection during the last decade. For several immunosuppressive
drugs, clinical development halted because they weren’t sufficiently effective or more toxic.
Areas covered: Current methods of monitoring Tac treatment, focusing on traditional therapeutic drug
monitoring (TDM), controversies surrounding TDM, novel matrices, pharmacogenetic and pharmacodynamic
monitoring are discussed.
Expert opinion: Due to a narrow therapeutic index and large interpatient pharmacokinetic variability,
TDM has been implemented for individualization of Tac dose to maintain drug efficacy and minimize the
consequences of overexposure. The relationship between predose concentrations and the occurrence of
rejection or toxicity is controversial. Acute cellular rejection also occurs when the Tac concentration is
within the target range, suggesting that Tac whole blood concentrations don’t necessarily correlate with
pharmacological effect. Intracellular Tac, the unbound fraction of Tac or pharmacodynamic monitoring
could be better biomarkers/tools for adequate Tac exposure – research into this has been promising.
Traditional TDM, perhaps following pre-emptive genotyping for Tac-metabolizing enzymes, must suffice
for a few years before these strategies can be implemented in clinical practice.
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1. Introduction
Treatment with low-dose tacrolimus (Tac) combined with the
antimetabolite mycophenolate and glucocorticoids seems to
offer the best outcomes after kidney transplantation in terms
of renal function, allograft survival, and acute rejection rates,
as compared with ciclosporin (CsA)-based regimens [1]. More
than a decade ago, Tac largely replaced CsA as the calcineurin
inhibitor (CNI) of choice and has remained so ever since [2].
Nonetheless, although the introduction of modern immuno-
suppressive drugs has improved the short-term outcome after
transplantation, long-term allograft failure remains an impor-
tant problem with 3–5% of kidney allografts being lost
annually after the first transplant year [3,4]. Although the
causes of long-term kidney allograft failure are multifactorial,
chronic CNI-associated nephrotoxicity is considered an
important cause [5,6]. Tac exerts its immunosuppressive prop-
erties by inhibiting the phosphatase activity of calcineurin (CN)
after binding to the intracellular FK-binding protein 12
(FKBP12) [7]. This inhibition subsequently leads to decreased
de-phosphorylation and activation of the nuclear factor of
activated T cells (NFAT), which activates the transcription of
genes important for T cell activation including interleukin
(IL)-2 and interferon (IFN)-γ. This eventually results in a dimin-
ished inflammatory alloreactive response [8,9].
Belatacept is a novel, non-nephrotoxic immunosuppressive
agent which blocks the CD80/86–CD28 co-stimulatory signal
necessary for T cell activation [10]. Belatacept-based immunosup-
pressionmay result in improved long-term patient and graft survi-
val but it is less effective than Tac in preventing acute rejection
[11,12]. It thus remains to be seen whether belatacept will replace
Tac as the first-line immunosuppressive drug anytime soon [13–
15]. Multicenter, randomized clinical studies also showed higher
incidences of acute rejection and dnDSA development in the Tac
withdrawal or rapamycin-based groups compared with Tac-based
regimen [1,3,16,17] In the foreseeable future, noothernovel immu-
nosuppressants are likely to emerge that can replace Tac.
2. Therapeutic drug monitoring
Due to a narrow therapeutic index and its large interpatient and
intrapatient pharmacokinetic variability, therapeutic drug mon-
itoring (TDM) is routinely performed for individualization of the
Tac dose to maintain drug efficacy and minimize the conse-
quences of overexposure [18]. As allografts are nowadays rarely
lost as a consequence of acute rejection, adverse events
CONTACT Dennis A. Hesselink d.a.hesselink@erasmusmc.nl Erasmus MC University Medical Center Rotterdam, Dept. of Internal Medicine Division of
Nephrology and Renal Transplantation, Room D-427, P.O. Box 2040 3000 CA Rotterdam, The Netherlands
*These authors contributed equally to this work.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2017
VOL. 13, NO. 12, 1225–1236
https://doi.org/10.1080/17425255.2017.1395413
© 2017 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/),
which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
D
ow
nl
oa
de
d 
by
 [E
ras
mu
s U
niv
ers
ity
] a
t 0
6:1
8 1
5 D
ec
em
be
r 2
01
7 
associated with long-term immunosuppression have become
increasingly evident [19]. Reducing the toxic effects of immuno-
suppression has become a major goal in the treatment of trans-
plant recipients [20]. The most frequently used means of Tac
monitoring is the measurement of the predose concentration
(C0) in whole blood. Some clinicians have started to question the
current reliance on C0 when performing TDM of Tac, with
instances of toxicity and rejection occurring when C0 are within
‘acceptable’ ranges. Amongst the transplant professionals, there
is an ongoing debate as to whether the Tac C0 sufficiently pre-
dicts kidney transplant rejection (see below) [21].
3. Controversies of TDM
The target Tac concentrations depend on the time after trans-
plantation, immunosuppressive comedication and the pre-
sumed risk of rejection. Therapeutic ranges developed for
Tac have not generally been based on statistical approaches,
but rather on a mixture of empirical observations, in quite
small samples of patients. In the past 20 years, there has
been a substantial change in the target Tac concentration
after kidney transplantation, with target concentrations as
high as 20 ng/mL in the early 1990s, and with targets as low
as 3–7 ng/mL after the publication of the Symphony-Elite
study [3]. However, only few studies have compared different
Tac concentration ranges and there is little support to pro-
mote the use of a specific therapeutic window and aim for
certain target concentrations [21].
3.1. Controversies of Tac exposure C0 with rejection
One of the reasons why the optimal target concentration is still
debated is the fact that the relationship between Tac exposure
(measured by C0) and the risk of graft rejection is controversial
(Table 1). A multicenter trial reported the association between low
whole-blood Tac C0 and the incidence of acute rejection in renal
transplantation. The Tac regimens were designed to produce low
(5–14 ng/ml), medium (15–25 ng/ml), or high (26–40 ng/ml)
whole-blood C0. A significant association was observed for
decreasing rates of rejection with increasing Tac exposure. The
authors suggested that the target range of whole-blood C0 that
optimizes efficacy and minimizes toxicity was 5–15 ng/ml during
the first 42 days of treatment [22]. In the same year, 92 kidney
transplant recipients and 721 liver transplant recipients from four
clinical trials were analyzed. The Tac concentration range was also
divided into low (5–14 ng/ml), medium (15–25 ng/ml), or high
(26–40 ng/ml) in renal transplant recipients. Again a significant
correlation between Tac C0 and the incidence of rejection was
found in renal transplant recipients [23]. In 1999, Undre et al.
reported that the mean AUC during the early posttransplant
period of Tac is significantly lower in patients who experience
acute rejection than those who remain rejection free. They sug-
gested that in order to reduce the risk of rejection, a Tac C0 of
10 ng/mL should be achieved by day 2–3 after transplantation
[24]. A decade later, Borobia et al. performed a receiver operating
characteristic (ROC) curve analysis to determinewhether particular
Tac C0 concentrations measured in the first week could discrimi-
nate between patients with an acute rejection and those who
experienced no rejection.
Patients with a Tac C0 below 9.3 ng/mL on day 5 showed a
shorter graft survival in comparison with patients with Tac C0
above this concentration [26]. A similar conclusion was also
drawn by Staatz et al., who estimated that a rejection rate as
high as 55%would be found for patients with a Tac C0 between 0
and 10 ng/ml, compared with no observed rejection in patients
with a Tac C0 between 10 and 15 ng/ml in the first month after
kidney transplantation [25]. They suggested that in order to
minimize rejection in the first month after renal transplantation,
Tac C0 had to be maintained above 10 ng/ml [25]. Gatault et al.
recently compared the efﬁcacy and safety of two different doses
of extended-release Tac (TacER) in kidney transplant recipients
between 4 and 12 months after transplantation. Stable steroid-
free kidney transplant recipients were randomized (1:1) after
4 months. Group A (n = 87) had a 50% reduction in TacER dose
with a targeted TacER C0 of 3 ng/mL or higher; whereas group B
(n = 99) had no change in TacER dose (TacER C0 7–12 ng/mL). The
authors observed that the eGFR was similar in both groups at
12 months, while more rejection episodes and inflammation
occurred in group A than in group B. They suggested that the
TacER C0 should be kept above 7 ng/mL during the first post-
operative year. However, the results of this study should be
interpreted in relation to the fact that steroid-free patients
were included who were receiving an average mycophenolate
mofetil (MMF) between 1 and 1.5 g/day [28].
In contrast, other studies in renal transplantation did not find
an association between plasma or whole-blood Tac concentra-
tions and the risk of acute rejection [27,29]. In a recent study, data
from three clinical trials were pooled (n = 1304) and analyzed. No
correlation was found between the Tac C0 measured at five time
points (day 3, 10, and 14, and month 1 and 6 after transplanta-
tion) and the occurrence of acute rejection in the period there-
after, in the first posttransplant year [21].
Based on the available literature, we conclude that shortly
after the introduction of Tac into clinical practice in the 1990s,
despite high target concentrations, acute rejection rates did
reach 40% or more [25]. This remarkably high incidence of rejec-
tion can be explained by the limited experience with this drug
and the concomitant use of azathioprine instead of MMF and/or
the lack of induction therapy. The introduction of MMF and anti-
IL-2 receptor antibody and T cell depleting antibody therapy in
Article highlights
● Acute cellular rejection can occur when the tacrolimus concentration
is within the target concentration range, demonstrating that tacroli-
mus whole blood concentrations do not always fully reflect its
pharmacological effect.
● Immunoassays remain the backbone of assay services for tacrolimus
now, so we must ensure that they are being used correctly.
● A high tacrolimus intra-patient variability is considered a risk factor
for poor long-term transplantation outcomes.
● Other strategies for TDM, including pharmacodynamic monitoring,
are promising clinical tools to ensure adequate tacrolimus exposure
and optimal efficacy of the drug.
● Pharmacogenetics-assisted tacrolimus monitoring, especially when
incorporated in dosing algorithms, could be useful to determine
the starting dose of tacrolimus
This box summarizes key points contained in the article.
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Tac-treated patients led to a dramatic reduction of rejection rates
to percentages below 20% [30]. The current strategy to target
low-medium Tac exposure seems reasonable. The lower end of
the Tac concentration range has not been clearly established but
it is unlikely that a trial comparing different Tac concentration
ranges will ever be performed in the era of modern
immunosuppression.
3.2. Controversies of Tac exposure C0 with toxicity
The relationship between Tac C0 and toxicity appears to be
stronger than with rejection. Several studies have demonstrated
a correlation between high blood Tac concentrations and toxi-
city, particularly nephrotoxicity [22,23,29,31]. In the multicenter,
open-label, concentration-ranging renal transplant trial, a signifi-
cant trend was observed for increasing toxicity with increasing
maximum Tac C0 [22]. The relationship between Tac C0 and
toxicity was clearly established in a study which combined the
data of four trials in both kidney and liver transplant recipients
[23]. These toxicities included ‘renal dysfunction’ and ‘any toxicity
requiring a dose reduction.’ The authors demonstrated that the
incidence of toxicity requiring a dosage reduction increased
significantly with increasing Tac C0. With the high-dose Tac regi-
men (0.2 mg/kg, twice daily, 26–40 ng/ml), the incidence of
toxicity was 62.1%, compared with 50% in the medium-dose
regimen (0.15 mg/kg, twice daily, 15–25 ng/ml) and 33.3% in
the low-dose regimen (0.1 mg/kg, twice daily, 5–14 ng/ml). In
1999, Bottiger et al. also concluded that side effects (one ormore)
were closely related to Tac exposure: 76% of Tac C0 above 30 ng/
ml, 41% of C0 within the interval of 20–30 ng/ml, and 26% of the
C0 within the interval of 10–20 ng/ml and only 5.3% for Tac
concentrations below 10 ng/ml. The authors recommended
that Tac whole-blood C0 should preferably be kept below
20 ng/ml to avoid side effects [27].
The large variability in the pharmacokinetics of Tac makes it
difficult to predict what drug concentration will be achieved
with a particular dosage or after a change in drug dose [32].
Without TDM, the large interpatient variability in Tac pharma-
cokinetics would be unnoticed, and extremes in Tac exposure
could occur, exposing some patients to toxic levels while
others are at risk for rejection due to too low exposure.
Despite the controversies surrounding TDM and the proposed
targets, TDM is still considered as the standard care after
transplant and widely used in clinical practice nowadays.
3.3. Monitoring TDM with AUC
The area under the concentration versus time curve (AUC) is
the best marker of Tac exposure. However, in many centers, it
is not feasible to perform TDM by means of a full-dosing
interval AUC because of logistic and financial constraints. In
addition, it poses a considerable burden on patients. Another
limitation of TDM by means of Tac AUC is the absence of hard
evidence to support targeting a specific AUC. Nonetheless,
some centers prefer to monitor Tac by means of AUC [33].
Calculation of the AUC based on a limited number of blood
samples strategy (LSS) using Bayesian estimation has been
proposed as a solution [34].
It is unclear which Tac AUC should be targeted in both the
early- and late-phase after kidney transplantation. Undre et al.
and Squifflet et al. both suggested an AUC >200 ng/h/mL in
the early phase after transplantation to be highly discrimina-
tory for the risk of acute rejection [24,35]. The study by
Scholten et al. performed an AUC-guided dosing study in 15
renal transplant recipients. Targets for AUC were as follows:
210 ng/h/mL for weeks 2–6 (corresponding with a C0 of
12.5 ng/mL) and 125 ng/h/mL for weeks 6–52 (corresponding
with a C0 of 7.5 ng/mL). The authors suggest an AUC target of
150–200 ng/h/mL [36]. However, since the publication of the
Symphony-Elite study [1], which demonstrated lower rates of
acute rejection and improved graft function associated with
low-exposure Tac (target C0 3–7 ng/mL) in combination with
MMF and glucocorticoids, the corresponding AUC may be
targeted to a lower range.
Before any new monitoring strategy can be recommended,
further studies are required to clarify the relationship between
(abbreviated) AUC monitoring and clinical outcome. For popu-
lation pharmacokinetic models and Bayesian forecasting to be
useful clinically, this next step must be taken to evaluate how
closely dosage predictions with these models actually achieve
AUC targets and improve clinical outcomes.
3.4. Analytical issues
Immunoassays have been used for routine TDM because of their
quick turnaround time, lower costs, and less complex method
(from the records of the International Tac Proficiency Testing
Scheme) [37]. It is well known that some Tacmetabolites including
M-1 (13-O-desmethyl tacrolimus, 10% of the immunosuppressive
activity of Tac), M-II (31-O-desmethyl tacrolimus, immunosuppres-
sive activity comparable to Tac), M-III (15-O-desmethyl tacrolimus,
no activity), M-V (15,31-di-O-desmethyl tacrolimus, no activity)
show cross-reactivity with immunoassays [38]. Up to 30% of Tac
quantification may be due to nonspecific detection [37]. Liquid
chromatography-tandem mass spectrometric detection (LC-MS/
MS) is now increasingly being implemented as a cost-effective
alternative technology for Tac TDM. LC-MS/MS is the technique of
choice because of its ability to separate and simultaneously quan-
tify Tac and its metabolites. In patients with low plasma concen-
trations of albumin, the results of Tacmeasurement as determined
by immunoassay are likely to be higher compared with LC-MS/MS
in the early post-surgery period. The correlation of albumin with
the interassay differences may possibly be explained by the pre-
sence of unbound Tac or metabolites with a lower affinity for
albumin, still able to cross-react with the antibody [39]. Some
studies found that immunoassays appear unable to analyze Tac
concentrations in the lower concentration range (between 3.0 and
5.0 ng/mL) and have a higher coefficient of variation (CV) [40]. Tac
concentration measurement by LC-MS methods have higher sen-
sitivity, precision, and accuracy, while the application of LC-MS in
individual centers is limited. Partly, this was because of inadequate
upfront payment for chromatography and difficulties in operation
and maintenance. Many centers analyze too few Tac samples to
justify the investment in LC-MS. Current data suggest that immu-
noassays will remain the backbone of assay services for Tac, so we
must ensure that they are being used correctly and that the data
are useful for clinical practice [36].
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TDM of Tac is usually performed in whole blood after venous
blood sampling. Dried blood spot (DBS) sampling might be an
alternative. In DBS sampling, blood is obtained via a finger prick
with a lancet. The drop of blood is applied to sampling paper,
which is dried and posted to a laboratory [41]. An advantage of
using DBS for TDM is that patients can collect the DBS at home
and no phlebotomist is necessary. This technique opens up the
possibility to perform extensive pharmacokinetic studies in
patients at home. There is, however, a need for more standardi-
zation, quality assurance, basic research, and assay development
before DBS can be widely implemented in TDM of Tac [42]. In
addition, it would be extremely useful if multiple components
could be assessed in the same sample. Of note, a DBS assay that
measures other immunosuppressants and serum creatinine
would meet a clinical need [43,44].
3.5. Intrapatient variability
In addition to being highly variable interindividually, Tac pharma-
cokinetics can also fluctuate within an individual patient. This so-
called intrapatient variability (IPV) is defined as the fluctuation in
Tac blood concentrations within an individual over a certain per-
iod of time during which the Tac dose is left unchanged (for an in-
depth review of Tac IPV please see reference [45]). A high Tac IPV is
considered a risk factor for poor long-term outcomes after kidney
transplantation, and similar findings have been reported after liver
[46] and lung transplantation [47]. The first evidence for the clinical
importance of Tac IPV was obtained by Borra et al. who found that
the within-patient variability in Tac is a significant risk factor for
reaching a composite end point consisting of graft loss, biopsy-
proven chronic allograft nephropathy and ‘doubling in plasma
creatinine concentration in the period between 12 months post-
transplantation and last follow up [48]. A high Tac IPV was also
associated with more acute rejection after kidney transplantation
[49]. Recently, Sapir-Pichhadze et al. observed that a higher Tac IPV
was associated with more late allograft rejection, transplant glo-
merulopathy, graft loss, and death with a functioning transplant
[50]. In pediatric kidney transplantation, a high Tac IPV has also
been associatedwith increased late rejection and graft loss [51,52].
Several factors can influence Tac pharmacokinetics and con-
tribute to Tac IPV, including the type of analytical assay (see
above), the concomitant intake of food, gastrointestinal distur-
bances, drug–drug interactions, genetic factors and importantly,
non-adherence [45,53–55]. Calculation of Tac IPV is relatively easy
and can be done automatically in the electronic patient record or
by use of apps, and may help to identify high-risk patients during
routine follow-up visits to the outpatient clinic. Once a patient is
recognized as having a high IPV, physicians need to find out what
is the underlying cause and try to resolve the problem [56].
Education with regard to the effects of food and over-the-counter
medication on Tac exposure should be attempted. When non-
adherence is suspected, interventions aimed at improving drug
compliance and possibly, switching to a Tac once-daily formula-
tion should be considered [57].
3.6. Drug–drug interactions
Drug interactions occur when the efficacy or toxicity of a medi-
cation is changed by coadministration of another drug. As Tac is
a substrate for cytochrome P450 (CYP) 3A enzymes and P-gp,
drugs that inhibit or induce these mechanisms may increase or
decrease blood Tac concentrations, such as glucocorticoids and
antifungal agents. Detailed knowledge of potential drug–drug
interactions with immunosuppressive drugs to avoid significant
clinical effects is of great importance in the clinical management
of transplant patients [53].
Tac drug interactions have been extensively studied [58–
61]. Drug interaction with P-gp may change Tac tissue distri-
bution and modify its toxicity and immunosuppressive activity
[62]. There is also evidence that ethnic and gender differences
exist for Tac drug interactions [63].
3.7. Once-daily Tac
Tacwas originally formulated as Prograf®. Newer once-daily (QD)
prolonged-release formulations of Tac (Advagraf® and
Envarsus® XR) and various generic versions of Prograf® are
becoming available now. The Envarsus® XR formulation using
MeltDose® technology was introduced as an innovation in the
field of the immunosuppressive drugs [64]. Envarsus® XR is
associated with consistent Tac exposure (AUC) at an approxi-
mately 30% lower dose compared to twice-daily Tac. On the
basis of the stricter criteria for narrow therapeutic-index drugs,
Prograf®, Advagraf® and Envarsus® XR are not bioequivalent.
Patients may require a daily dosage increase if converted from
Prograf® to Advagraf®, while a daily dosage reduction appears
necessary for conversion from Prograf® to Envarsus® XR [65].
Studies found similar results for both once-daily formulations in
terms of patient survival, graft survival and renal function [66,67].
One recently published review concluded that once-daily Tac is
non-inferior to twice-daily Tac, with a concentration-dependent
risk of rejection risk [68]. For the toxicity, some studies suggested
that once-daily Tac may have favorable effects on blood pressure,
the lipid profile and glucose tolerance [68–70]. Larger randomized,
controlled trials are needed in different transplant populations to
determine whether there are differences in efficacy and toxicity
across the formulations and whether formulation conversion is
worthwhile in the long term.
There is also a trend for improved adherence with QD formula-
tion [71] and in one study, patients stated a preference for once-
daily Tac dosing [72]. In addition to improved adherence, studies
showed that after conversion, intraindividual variability appears to
be lower with Tac QD [73,74]. A close monitoring of C0 levels, or
Bayesian estimation of the AUC when needed, is mandatory
because of the high interindividual variability in Tac pharmacoki-
netics [75,76].
4. Novel matrices
4.1. Intracellular Tac
As the site of action of Tac is within the lymphocyte, it seems
logical to assume that the Tac concentration at its target site is
more relevant than the concentration in whole blood to predict
the efficacy of treatment [77]. Over the last few years several
assays have been published that were able to measure Tac in
peripheral blood mononuclear cells (PBMC), obtained following
gradient density centrifugation. In 2007, the first published assay
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was an immunoassay [78], but since then several (UP)LC-MS/MS
assays have been published [79–81]. Capron et al. studied the
intracellular Tac concentration in 96 renal transplant recipients.
They concluded that the intracellular concentrations seemed to
be strongly dependent on ABCB1 polymorphisms [82]. Based on
histological findings, there tended to be an association between
acute rejection episodes and significantly lower Tac intracellular
concentrations [82]. The same research group conducted a study
in liver transplant recipients and observed that patients experi-
encing clinical rejection one week after transplantation had sig-
nificantly lower Tac PBMC concentrations on day 7 after
transplantation than patients who did not suffer from a rejection
episode. In contrast to the intracellular concentration, the whole-
blood Tac concentration was not associated with clinical rejec-
tion. The authors concluded that the Tac concentration in PBMCs
could be a better matrix for the measurement and TDM of Tac
[83]. Lemaitre et al. failed to demonstrate a relationship between
Tac whole-blood concentrations, Tac PBMC concentrations, and
intracellular CN activity. This was probably caused by the small
cohort of patients (n = 10) [84]. That same year Pensi et al. were
able to characterize the PBMC compartment as a significant Tac
reservoir in 37 pediatric liver transplant recipients, with intracel-
lular concentrations being approximately 12.7 times higher than
whole-blood concentrations. For the first time, a correlation
between intracellular and whole-blood concentrations was
demonstrated [81]. Fairly recently, the relationship between Tac
concentrations in PBMCs, the whole-blood Tac concentration,
the factors affecting this relationship, and the risk of rejection
was studied in 237 renal transplant recipients [85]. The correla-
tion between whole-blood and intracellular Tac concentration
was linear. This relationship was affected by sex, hematocrit, and
time after transplantation. The Tac ratio (intracellular concentra-
tion divided by whole-blood concentration) was not significantly
associated with acute rejection [85].
The intracellular Tac concentration could be a better matrix
to ensure adequate Tac exposure in addition to whole-blood
Tac levels. The major drawback of implementing intracellular
Tac concentration measurement in clinical practice is the com-
plex analytical technique. Furthermore, there is only limited
evidence that the intracellular concentration correlates better
with clinical outcomes than whole blood exposure. Given the
fact that one of the determinants of the ratio between intra-
cellular and whole-blood Tac concentration is the activity of
efflux pumps in the cell membrane of PBMCs, and as poly-
morphisms in the genes encoding for these pumps will result
in different ratios between individuals, it is expected that
intracellular concentration will offer a better reflection of bio-
logical action than whole blood Tac concentrations.
4.2. Unbound Tac concentration
The disposition of Tac is affected by protein binding. The
unbound concentration of a drug is considered the pharmaco-
logically active part. This may be attributed to the fact that only
unbound drug in plasma can migrate to tissue compartments
and interact with its receptor. It thus seems reasonable to assume
that the unbound or free, Tac concentration may predict the
efficacy or toxicity of treatment better than whole-blood
concentrations. The unbound concentration of Tac is low (<3%
of the total plasma concentration and <0.5% of the whole-blood
concentration) [86]. In 2004, the distribution and plasma protein
binding of Tac was studied in 40 liver transplant recipients. The
unbound fraction was significantly lower in patients experien-
cingmild rejection compared to patients who did not experience
a rejection episode (0.32 and 0.53, respectively). Interestingly, no
difference was observed for total whole-blood concentrations
between rejecting and non-rejecting patients [87]. A second
study in 10 liver transplant recipients also showed significantly
lower unbound Tac concentrations during rejection episodes. In
patients experiencing Tac-related side effects, the unbound Tac
concentration was significantly higher (0.84 ± 0.19 vs. 0.53 ± 0.19
ng/L). The whole-blood concentrations were not different for
both rejection and toxicity [88]. These studies support the lack
of correlation between Tac whole-blood concentration and the
incidence of rejection and side effects, and suggest that the
unbound Tac concentration could be a better predictor of Tac
efficacy.
Due to the complex analytical technique, not much
research was published on unbound Tac concentrations the
last decade. Fairly recently, a novel, and less complex LC-MS/
MS method was published [86]. This will hopefully facilitate
more research on the relationship between unbound Tac and
clinical outcomes.
5. Pharmacogenetic monitoring
Genetic polymorphisms in genes encoding Tac-metabolizing
enzymes partly explain the interpatient variability in Tac phar-
macokinetics. The key enzymes involved in the metabolism of
Tac are CYP3A4 and CYP3A5 [89]. Individuals are considered
expressers of CYP3A5 if they carry at least one CYP3A5*1 allele,
whereas individuals homozygous for the CYP3A5*3 allele are
classified as CYP3A5 non-expressers. In addition to CYP3A5*3,
the CYP3A5*6 and CYP3A5*7 variant alleles can also lead to
nonfunctional CYP3A5 protein [90]. There are also ethnic dis-
tribution differences of CYP3A5 variant alleles with expressers
(carriers of the CYP3A5*1 variant allele) being more frequently
found among non-Caucasian populations. Approximately
10–40% of Caucasians are CYP3A5 expressers, 33% of Asians
and 55% of African Americans [91–93]. CYP3A5 expressers
require a Tac dose that is approximately 1.5–2-fold higher
than non-expressers to reach the same exposure [94–96]. This
implies that following a standard, bodyweight-based Tac dose,
CYP3A5 expressers are prone to have subtherapeutic Tac con-
centrations whereas non-expressers are expected to have
supratherapeutic Tac concentrations [32]. Genetic testing
prior to the initiation of Tac treatment would allow to more
quickly reach the target concentration. The CPIC guideline
recommends that if CYP3A5 genotype of a transplant patient
is known, expressers should receive a 1.5–2 times higher start-
ing dose, while CYP3A5 non-expressers should get the standard
starting dose. The guideline, however, does not advise nor
discourage pharmacogenetic testing prior to the start of Tac
therapy [97].
Two large randomized-controlled trials have attempted to
determine the clinical relevance of basing the Tac starting dose
on an individual patient’s CYP3A5 genotype. In both trials, kidney
1230 L. M. ANDREWS ET AL.
D
ow
nl
oa
de
d 
by
 [E
ras
mu
s U
niv
ers
ity
] a
t 0
6:1
8 1
5 D
ec
em
be
r 2
01
7 
transplant recipients were randomized to either receive the
standard, bodyweight-based Tac dose (0.2 mg/kg/day) or to
receive a dose customized to the CYP3A5 status of the patient
(expressers 0.3 mg/kg/day and non-expressers 0.15 mg/kg/day)
[98,99]. In the first study, genotype-based dosing resulted in
significantly more patients being within the target Tac concen-
tration range, 3 days after starting Tac (43.2%), compared with
patients receiving the standard, bodyweight-based dose (29.1%).
The genotype-based group also required significantly less time
and fewer dose adjustments to reach the target Tac concentra-
tion [99]. The second trial, however, found no such advantage of
CYP3A5-based dosing with 37.4% of patients receiving the stan-
dard bodyweight-based dose beingwithin the Tac concentration
range comparedwith 35.6% of the genotype-based group at first
steady state. Therewas also no difference in the time to reach the
target Tac concentration or the number of dose adjustments
[98]. The explanation for this finding was that in the genotype-
based arm, CYP3A5 non-expressers tended to have subtherapeu-
tic concentrations more often after receiving the reduced start-
ing dose. The reverse was seen among CYP3A5 expressers in the
genotype-based arm, who tended to be above the target Tac
concentration [98].
Both trials, performed in largely Caucasian populations, failed
to demonstrate a decreased risk of acute rejection or any other
clinical benefit, concluding that optimizing the initial Tac dose
based on CYP3A5 genotype alone does not improve clinical out-
comes when extensive TDM is performed [100]. It appears that
TDM rapidly corrects any Tac concentrations outside the thera-
peutic concentration range and therefore the under- or over-
exposure does not last long enough to cause a clinically relevant
increase in the incidence of acute rejection or side effects. The
current outcome studies do not support routinely genotyping
kidney transplant recipients for CYP3A5. However, a genotype-
based strategy may hold promise for patients having a high
immunological risk and for ethnic populations with higher pre-
valence of CYP3A5 expresser status, such as Asians and African
Americans [101,102].
In both trials, the percentage of patients within the desired
Tac concentration range 3 days after initiating Tac was rather
low, implying that there is a considerable variability in Tac
pharmacokinetics that cannot be explained by CYP3A5 geno-
type alone. In Caucasians, polymorphisms in the CYP3A5 gene
explain 40–50% of the variability in Tac dose requirement
[98,99]. The CYP3A4 genotype has also been associated with
altered Tac clearance [89]. Fairly recently, research has shown
that CYP3A4*22 is associated with lower Tac dose requirements,
whereas CYP3A4*26 is associated with extremely low-dose
requirements [103–105].
Perhaps a more precise and novel strategy is to use a pharma-
cokinetic dosing algorithm for the starting dose of Tac. Recently
developed algorithms usually incorporate the CYP3A5 genotype,
and occasionally also the CYP3A4 genotype. Moreover, these algo-
rithms use a combination of clinical, demographic, and genetic
information to determine the Tac dose [106]. So far, a few dosing
algorithms suitable to determine the starting dose have been
developed [107]. The most extensively researched dosing algo-
rithmwas developed by Passey et al. [108]. It incorporated CYP3A5
genotype, age, days posttransplant, steroid and calcium channel
blocker use. It was later successfully validated externally in an
independent cohort [109]. A few years later, this dosing algorithm
was prospectively tested by an independent research group and
unfortunately it was not able to predict the estimated Tac clear-
ance accurately [110]. Fairly recently, a dosing algorithm for the
starting dose and subsequent dosages was developed using data
from 304 renal transplant recipients [111]. The pharmacokinetic
model included CYP3A5*3, CYP3A4*22, age and hematocrit.
External validation confirmed the prediction ability of the model.
This algorithm has not been prospectively tested. Recently, a
dosing algorithm for the starting dose and subsequent dosages
of Tac following pediatric renal transplantation was published
[112]. Recipients with a higher bodyweight, lower eGFR, higher
hematocrit levels, CYP3A5 non-expressers and who received a
kidney from a living donor, had a lower Tac clearance. The phar-
macokinetic model was successfully externally validated. The dos-
ing algorithm is currently being tested in a prospective study. To
our knowledge other dosing algorithms, developed in children or
adults, have not been validated externally nor tested prospec-
tively. We feel that this is essential before these dosing algorithms
can be implemented in routine clinical practice.
6. Pharmacodynamic monitoring
6.1. Calcineurin activity
CN activity assays directly measure the effect of CNIs on their
target enzyme CN. This enzyme is selectively targeted by CNIs
and can therefore be used to monitor the pharmacodynamics of
Tac [113]. Van Rossum et al. published a comprehensive review on
this topic in which the pros and cons of this assay were extensively
discussed [114]. Quantifying the degree of inhibition of CN deter-
mines the biological effect/pharmacodynamics of Tac and may
better reflect the biological effect of Tac, compared to pharmaco-
kinetic monitoring [115]. Data by Sellar et al. showed that the
activity of CN in patients treated with Tac correlated with CN
activity in whole blood, leukocytes, and PBMCs [116–118]. The
first hours after Tac intake, a clear inhibition of CN activity was
observed; however, after six hours CN activity could no longer be
distinguished from pre-intake CN activity, whereas whole-blood
concentrations were still elevated [117,118]. Mortensen et al.
demonstrated that on day 14 posttransplantation, the CN activity
before, as well as 1, 2, 3, and 4 h after oral intake of Tac, was
significantly inhibited compared with healthy subjects not treated
with a CNI. In contrast, in the same patients 5 years posttransplan-
tation, the CN activity measured at the same time points was not
significantly different from CN activity in healthy subjects, despite
relevant Tac concentrations [119]. This could be explained by the
lower doses and Tac target concentrations 5 years posttransplant,
but also raises the question whether monitoring the CN activity is
the correct pathway.
In both liver and kidney transplant recipients, the CN activity
just before intake of the next Tac dose was increased in patients
suffering from acute rejection [120,121]. Fukudo et al. demon-
strated that the CN activity rapidly increased a few days before
onset of acute rejection [122]. However, all the CN activity studies
were conducted in small groups of patients. The correlation
between CN activity and clinical events, e.g. acute rejection or
Tac toxicity in renal transplantation therefore remains unclear
[114]. In our opinion, CN activity measurement is currently not a
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clinically useful marker for TDM of Tac [123]. Furthermore, the
analytical techniques to measure CN are complex, time consum-
ing, and expensive.
6.2. Expression of nuclear factor of activated T-cell-
regulated genes
Another biomarker that may reflect the individual’s sensitivity to
CNI therapy is the assessment of NFAT-regulated gene expression.
CNIs inhibit the transcription of the NFAT-regulated genes IL-2,
IFN-γ, and granulocyte macrophage colony-stimulating factor
(GM-CSF) in lymphocytes [124,125]. The expression of
NFAT-regulated genes in patients treated with Tac, shows an
inverse correlation between Tac whole-blood concentrations and
the expression of these genes [126]. At the time of peak Tac
concentrations, the highest inhibition of gene expression
occurred. Data on NFAT-regulated gene expression are more
comprehensive in CsA therapy, compared with Tac therapy [127].
The first study on NFAT-regulated gene expression in renal
transplant recipients treated with Tac, demonstrated that the
residual expression of NFAT-regulated genes was significantly
higher in patients with acute rejection, whereas the Tac predose
concentrations were comparable. Of the patients with gene
expression above 30%, a quarter developed BPAR [126]. A small
study in liver transplant recipients showed similar results [128].
Two prospective observational studies concluded that low
NFAT-residual gene expression was associated with signs of
over-immunosuppression, including CMV and BKV viremia
[127,129]. A small study in liver transplant recipients demonstrated
a lower NFAT-regulated gene expression in patients with CMV-
viremia [130]. NFAT-regulated gene expressionmight be used as a
biomarker for detecting patients with an increased risk of rejection
or virus-associated complications.
An RCT is currently being performed which evaluates the
improvement of cardiovascular risk in CsA-treated stable renal
transplant recipients by monitoring the CsA C0 and residual
NFAT-regulated gene expression [127]. Secondary objectives
include the incidence of BPAR, adverse events, and renal function
[127]. To our knowledge, no such studies in Tac-treated patients
are currently being executed. NFAT-regulated gene expression is
less specific for Tac exposure than measuring CN activity, but it
seems easier and more reproducible. At this moment in time,
NFAT-regulated gene expression is not a useful clinical marker
for adequate Tac exposure but in the future it could possibly be
used in addition to TDM.
6.3. Phosphospecific flow cytometry
Cytokines binding to the IL-2 receptor family act via activation of
the Janus kinase-signal transducer and activator of transcription
(JAK-STAT) pathway. JAK enzymes are key elements in cytokine
signaling. JAKs phosphorylate the γc receptor of the IL-2R that
subsequently serves as docking molecule for the STAT signaling
molecules. Vafadari et al. published a comprehensive review on
this topic [131]. For other cytokines e.g. IL-6, IL-10, IL-17 and
interferons, JAK-STAT activation is also critical for signaling.
Phosphospecific flow cytometry measures activation-induced
changes of signaling molecules and can be used to monitor
the effect of immunosuppressive drugs on intracellular signaling
pathways and how molecules are activated in response to sti-
muli [131].
NF-κB plays a key functional role in T cell activation and is
considered a mediator of rejection processes following organ
transplantation [132,133]. The effect of Tac on the NF-κB
activation pathway was studied by quantitative analysis of
NF-κB phosphorylation in primary T cell subsets. This study
concluded that Tac has a suppressive effect on NF-κB signaling
in peripheral T cell subsets [134].
It was recently discovered that Tac also suppresses the phos-
phorylation of the mitogen-activated protein kinase (MAPK) path-
way [135]. The amount of phosphorylation of this signaling
molecule seems to be inversely correlated with Tac C0 in kidney
transplant patients. Increased p38MAPK phosphorylation was
associated with higher T cell activation status. Recent research
has shown that conversion to once-daily Tac results in increased
p38MAPK phosphorylation in T cells of kidney transplant patients
[136]. Three months post conversion, p38MAPK phosphorylation
increased significantly in CD4+ (11.4%) and in CD8+ (15.6%) T
cells, whereas the Tac C0 did not decrease significantly [136].
Another study demonstrated that Tac inhibits p38MAPK phos-
phorylation by 30% in CD14+ monocytes [137]. Tac also partially
inhibited p-AKT (14%) and p-ERK (extracellular signal-regulated
kinases, 15%) [137]. Activation of these pathways plays an impor-
tant role in monocyte/macrophage responses. The authors con-
cluded that Tac does not strongly affect monocyte function [137].
The observations in the above-mentioned pharmacody-
namic studies suggest that measuring NF-κB or p38MAPK
phosphorylation may better reflect the biological effects of
Tac therapy compared with classic pharmacokinetic monitor-
ing. More precise information on T cell activation status is
obtained, but the relationship between NF-κB or p38MAPK
phosphorylation and acute rejection is yet to be established.
7. Expert opinion
Immunosuppressive therapy is necessary to prevent both acute
and chronic rejection after kidney transplantation. Tac is the
preferred drug and it is to be expected that in the next 10 years,
patients will continue to receive Tac as part of standard immu-
nosuppressive regimens.
Due to a narrow therapeutic index and large interpatient
pharmacokinetic variability, TDM is routinely performed for indi-
vidualization of the Tac dose to maintain drug efficacy and
minimize the consequences of under- and overexposure.
Unfortunately, the evidence for the optimal Tac C0 is more
limited than one would expect of a drug so extensively pre-
scribed and studied. Based on the current literature, there is little
support to promote a specific therapeutic window. Besides this,
the relationship between Tac concentration and either acute
rejection or toxicity remains controversial. Acute cellular rejec-
tion episodes occur when the Tac concentration is within the
target concentration range and patients having supra-therapeu-
tic exposure sometimes do not suffer from side effects. This
suggests that Tac whole-blood predose concentrations do not
always correlate with its pharmacological effect and indicate that
novel matrices or monitoring strategies are needed to better
predict and monitor the effect of Tac treatment.
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Novel options include the measurement of Tac concentra-
tions within the lymphocyte and the unbound concentration.
Both options are technically demanding but seem feasible
with the recent availability of sophisticated analytical meth-
ods. The intracellular Tac concentration is the most extensively
studied option of the two. An association between the Tac
PBMC concentration and acute rejection has been demon-
strated and at this point in time is the most promising matrix
to optimize the monitoring of Tac. Nonetheless, results need
to be consistent before we can abandon classic TDM.
As Tac is mainly metabolized by CYP3A5, and as it is known
that CYP3A5 expressers require a twofold higher dose to reach
the same exposure compared with non-expressers, it seems
reasonable to implement preemptive pharmacogenetic testing.
However, two RCTs failed to demonstrate a decreased risk of
acute rejection or any other clinical benefit of basing the Tac
starting dose on an individual’s CYP3A5 genotype. More sophis-
ticated dosing strategies are needed. A more precise strategy
would be to develop and validate a population pharmacokinetic
dosing algorithm for the initial Tac dose. Implementation of a
dosing algorithm may allow recipients to reach the target Tac
concentration more quickly and may lead to less patients being
exposed to extremely high or low Tac concentrations.
A relatively unknown but promising technique is the pharma-
codynamic monitoring of Tac. Different strategies are currently
under investigation, of which measuring the NFAT regulated
gene expression or phosphospecific flowcytometry show the
most encouraging results. It is possible that after two decades
of Tac predose concentration measurements and TDM, in a few
years pharmacodynamic monitoring will be conducted in com-
bination with classic TDM to adequately describe the effect of
Tac. With no new immunosuppressive drugs in the pipeline, an
improved monitoring strategy of Tac seems the next best thing
to optimize patient outcomes.
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